Schechter Max S, Widman Linnea, Wester Axel, Shang Ying, Stål Per, Fortune Brett, Hagström Hannes
Albert Einstein College of Medicine, Bronx, New York, USA.
Department of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Aliment Pharmacol Ther. 2025 Jan;61(1):109-121. doi: 10.1111/apt.18309. Epub 2024 Oct 1.
Timely transition of care amongst patients with a first diagnosis of cirrhosis in a hospital to an outpatient visit is important. We evaluated rates of outpatient follow-up after a first diagnosis of cirrhosis during an inpatient setting, and its association with subsequent rates of rehospitalisation and mortality.
We conducted a population-based cohort study identifying all hospitalised patients in Sweden diagnosed with cirrhosis between 2002 and 2020 from the Swedish National Patient Register. The primary outcome was any outpatient visit related to cirrhosis within 90 days after hospital discharge. Secondary outcomes were rates of rehospitalisation and mortality within 1 year of discharge in patients receiving outpatient follow-up within 90 days or not. Cox regression was used for all analyses, and incidence rates per 1000 person-years were calculated for mortality and rehospitalisation.
Of 8852 patients, 3759 (42%) had outpatient follow-up within 90 days of discharge. Patients who received follow-up within 90 days of discharge were younger, had a higher level of education and were more likely to have liver decompensation or hepatocellular carcinoma compared to those without timely follow-up. We found that follow-up within 90 days was associated with lower rates of all-cause mortality within 1 year (aHR = 0.86, 95%CI = 0.78-0.96) but with no significant impact on rehospitalisations (aHR = 0.97, 95%CI = 0.91-1.03).
In Sweden, 42% of hospitalised patients with newly diagnosed cirrhosis receive outpatient follow-up within 90 days of their hospital discharge. These patients may experience lower mortality but no change in rehospitalisations within 1 year.
医院中首次诊断为肝硬化的患者及时实现护理过渡至门诊就诊很重要。我们评估了住院期间首次诊断为肝硬化后的门诊随访率,及其与随后再住院率和死亡率的关联。
我们进行了一项基于人群的队列研究,从瑞典国家患者登记处识别出2002年至2020年间在瑞典被诊断为肝硬化的所有住院患者。主要结局是出院后90天内与肝硬化相关的任何门诊就诊。次要结局是在出院后1年内,90天内接受门诊随访或未接受门诊随访的患者的再住院率和死亡率。所有分析均使用Cox回归,并计算每1000人年的死亡率和再住院率的发病率。
在8852例患者中,3759例(42%)在出院后90天内接受了门诊随访。与未及时接受随访的患者相比,出院后90天内接受随访的患者更年轻,受教育程度更高,更有可能出现肝失代偿或肝细胞癌。我们发现,90天内的随访与1年内全因死亡率较低相关(调整后风险比[aHR]=0.86,95%置信区间[CI]=0.78-0.96),但对再住院率无显著影响(aHR=0.97,95%CI=0.91-1.03)。
在瑞典,42%新诊断为肝硬化的住院患者在出院后90天内接受门诊随访。这些患者可能死亡率较低,但1年内再住院率无变化。